Bionano Genomics, Inc. is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr system. The Company’s products include Sequencing for Discovery Research and Cytogenetics.
Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response. The Company’s subsidiary, Lineagen, Inc., provides molecular diagnostics services for individuals. (Source: Refinitiv)
BNGO, together with $ASXC (Asensus Surgical Inc.) , were two of my amazing choices at the end of 2020. BNGO, although it almost halved, is still 831% up for me. Despite that, the company has still a big potential, so let us look into the fundamentals:
🔹️ Market Cap of $2.34B
🔹️ Revenue of 16.4M in FY1 and 57.3M in FY3
🔹️ Revenue growth of over 90%!
🔹️ Short Interest at 13.1%
🔹️ Debt to Capital at 3.94%
🔹️ Cash of 362M
🔹️ Upside Potential 43%
In terms of Segments, 37% of Revenue is attributed to Consumables, 36% to Instruments and 27% to Services and Other. North America brings 53% of Revenue, 37% is generated in EMEA and 10% in Asia Pacific.